Objectives To evaluate the efficacy of subcutaneous of immunoglobulins (SCIg) in 13 patients with refractory polymyositis (PM) and dermatomyositis (DM).
Methods We described 13 patients (10 female and 3 male) with PM (5) and DM (8), diagnosed according to the Bohan and Peter's criteria, with a mean age of 50 years and a mean disease duration of 72 months. Prior SCIg treatment, all patients received high dose oral glucocorticoids associated to several immunosuppressive agents with no sustained improvement. Mean follow-up period was 20 months. We used a standardized protocol of infusion consisting on the administration of a weekly dose of 0.2 g/kg/week of SCIg, by the means of a programmable pump, changing sites of administration every week. After a three weeks of in hospital training period, patients were switched to home management.
Results Treatments response was evaluated using clinical and laboratory data. We documented a significant improvement on serum CK levels, MRC score and Rankin modified score. Prednisone daily dose was reduced in all patient. Neither systemic adverse events nor relapses were reported.
Conclusions Our data showed the effectiveness and the good tolerance of SCIg as a valid treatment option in active and severe form of myopathies, also as steroid-sparing agents. However, a longer follow-up period is necessary to evaluate their efficacy as an alternative to intravenous route of administration (IVIg treatment).
Disclosure of Interest None declared